JY BioMed's Founder Ethan Shen, PhD, and CMO Dr. Benjamin Zhang presented the γδ T cell therapy and Anti-CEACAM6 ADC platforms at the 85th Japanese Cancer Association Annual Meeting in Kyoto. Learn more about JY BioMed's international research initiatives.
